RxDoctor Payments Data

Rumi Lakha, DO

Family Medicine · Huntington Park, CANPI 1902092034

Payments from drug & device makers

$7,301in general payments, 2019–2025

Across 238 payments — averaging $30.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Vanda Pharmaceuticals Inc.$2K
  • GSK$1K
  • AstraZeneca$437
  • Smith+Nephew$321
  • Pfizer$252
  • plus $1K from 12 others

What the payments were for

  • Travel & lodging$50%
  • Food & beverage$7,296100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,301 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$727,097
Medicare patients
195
Services billed
19,837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate42$85,116
BiktarvyBictegrav/Emtricit/Tenofov Ala12$54,468
JanuviaSitagliptin Phosphate99$51,242
OzempicSemaglutide36$35,146
Diclofenac Sodium64$34,008
Tavaborole29$33,806
Dihydroergotamine Mesylate19$24,141
LinzessLinaclotide35$21,606
MounjaroTirzepatide19$20,881
Cyclosporine49$17,964
JardianceEmpagliflozin25$17,944
JanumetSitagliptin Phos/Metformin Hcl19$16,791
VascepaIcosapent Ethyl54$16,486
CreonLipase/Protease/Amylase13$15,987
TrulicityDulaglutide16$15,189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$2,401$37,59248 claims
Lilly USA, LLCMounjaro, Trulicity$251$36,07035 claims
Novo NordiskOzempic$240$35,14636 claims
Boehringer IngelheimJardiance, Tradjenta$96$24,84939 claims
PfizerEliquis$252$14,73118 claims
GSKTrelegy Ellipta$1,026$10,87218 claims
AstraZenecaFarxiga$437$7,66214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Huntington Park

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →